Skip to main content
SpringerLink
Log in

Current HCC Staging Systems: Their Uses and Limitations

  • Chapter
  • First Online:
Hepatocellular Carcinoma

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

Hepatocellular carcinoma (HCC) is a major health concern worldwide. The prediction of prognosis of HCC is complex compared with most solid tumors, because it depends on the tumor burden in addition to patient’s underlying liver disease and liver functional reserve. Therefore, staging systems based on both tumor factors and host factors such as liver function have been required to accurately classify HCC patients undergoing various therapeutic options. Although many staging systems and scoring systems have been established and refined in many countries, however, there is currently no globally accepted system for assessing HCC patients, due to heterogeneity of the extent of tumor extension and underlying liver disease. In this review, we focus on the currently available staging systems for assessing the prognosis of HCC, their uses, limitations, and future prospects.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.

    Article  PubMed  Google Scholar 

  2. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10(2 Suppl 1):S115–20. doi:10.1002/lt.20034.

    Article  PubMed  Google Scholar 

  3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. doi:10.1056/NEJMoa0708857.

    Article  CAS  PubMed  Google Scholar 

  4. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, et al. Management of hepatocellular carcinoma: report of consensus meeting in the 45th annual meeting of the Japan Society of hepatology (2009). Hepatol Res. 2010;40(7):667–85. doi:10.1111/j.1872-034X.2010.00673.x.

    Article  PubMed  Google Scholar 

  5. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2. doi:10.1002/hep.24199.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Duseja A. Staging of hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4(Suppl 3):S74–9. doi:10.1016/j.jceh.2014.03.045.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: current status and future perspectives. World J Hepatol. 2015;7(3):406–24. doi:10.4254/wjh.v7.i3.406.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, et al. Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol. 2008;23(3):445–52. doi:10.1111/j.1440-1746.2007.05075.x.

    Article  PubMed  Google Scholar 

  9. Maida M, Orlando E, Camma C, Cabibbo G. Staging systems of hepatocellular carcinoma: a review of literature. World J Gastroenterol. 2014;20(15):4141–50. doi:10.3748/wjg.v20.i15.4141.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907–17. doi:10.1016/s0140-6736(03)14964-1.

    Article  PubMed  Google Scholar 

  11. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10(11):1111–8. doi:10.1016/s1470-2045(09)70241-4.

    Article  PubMed  Google Scholar 

  12. Henderson JM, Sherman M, Tavill A, Abecassis M, Chejfec G, Gramlich T. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB (Oxford). 2003;5(4):243–50. doi:10.1080/13651820310015833.

    Article  CAS  Google Scholar 

  13. Kudo M. International comparison of treatment outcomes based on staging systems. Hepatol Res. 2007;37(Suppl 2):S216–22. doi:10.1111/j.1872-034X.2007.00188.x.

    Article  PubMed  Google Scholar 

  14. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245(6):909–22. doi:10.1097/01.sla.0000254368.65878.da.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002;20(6):1527–36.

    Article  PubMed  Google Scholar 

  16. Chen TW, Chu CM, Yu JC, Chen CJ, Chan DC, Liu YC, et al. Comparison of clinical staging systems in predicting survival of hepatocellular carcinoma patients receiving major or minor hepatectomy. Eur J Surg Oncol. 2007;33(4):480–7. doi:10.1016/j.ejso.2006.10.012.

    Article  CAS  PubMed  Google Scholar 

  17. Camma C, Di Marco V, Cabibbo G, Latteri F, Sandonato L, Parisi P, et al. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther. 2008;28(1):62–75. doi:10.1111/j.1365-2036.2008.03692.x.

    Article  CAS  PubMed  Google Scholar 

  18. Noda T, Sasaki Y, Yamada T, Eguchi H, Yano M, Ohigashi H, et al. Usefulness of the CLIP scoring system for prediction of postoperative prognosis of patients with large hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2009;16(4):538–45. doi:10.1007/s00534-009-0096-4.

    Article  Google Scholar 

  19. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut. 2005;54(3):411–8. doi:10.1136/gut.2004.048124.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Kim BK, Kim SU, Park JY, Kim do Y, Ahn SH, Park MS et al. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naive patients with hepatocellular carcinoma. Liver Int. 2012;32(7):1120–7. doi:10.1111/j.1478-3231.2012.02811.x.

    Google Scholar 

  21. Li X, Dong M, Lin Q, Chen ZH, Ma XK, Xing YF, et al. Comparison of current staging systems for advanced hepatocellular carcinoma not amendable to locoregional therapy as inclusion criteria for clinical trials. Asia Pac J Clin Oncol. 2013;9(1):86–92. doi:10.1111/ajco.12050.

    Article  PubMed  Google Scholar 

  22. Yan X, Fu X, Cai C, Zi X, Yao H, Qiu Y. Validation of models in patients with hepatocellular carcinoma: comparison of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging system in a Chinese cohort. Eur J Gastroenterol Hepatol. 2015;27(10):1180–6. doi:10.1097/meg.0000000000000418.

    Article  CAS  PubMed  Google Scholar 

  23. Cillo U, Bassanello M, Vitale A, Grigoletto FA, Burra P, Fagiuoli S, et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol. 2004;40(1):124–31.

    Article  PubMed  Google Scholar 

  24. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41(4):707–16. doi:10.1002/hep.20636.

    Article  PubMed  Google Scholar 

  25. Pascual S, Zapater P, Such J, Garcia-Herola A, Sempere L, Irurzun J, et al. Comparison of staging systems to predict survival in hepatocellular carcinoma. Liver Int. 2006;26(6):673–9. doi:10.1111/j.1478-3231.2006.01282.x.

    Article  PubMed  Google Scholar 

  26. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006;44(4):723–31. doi:10.1016/j.jhep.2005.12.015.

    Article  PubMed  Google Scholar 

  27. Guglielmi A, Ruzzenente A, Pachera S, Valdegamberi A, Sandri M, D’Onofrio M, et al. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol. 2008;103(3):597–604. doi:10.1111/j.1572-0241.2007.01604.x.

    Article  PubMed  Google Scholar 

  28. Zhang JF, Shu ZJ, Xie CY, Li Q, Jin XH, Gu W, et al. Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort. PLoS One. 2014;9(3):e88182. doi:10.1371/journal.pone.0088182.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Chen CH, Hu FC, Huang GT, Lee PH, Tsang YM, Cheng AL, et al. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method–analysis of 2010 Taiwanese patients. Eur J Cancer. 2009;45(9):1630–9. doi:10.1016/j.ejca.2008.12.025.

    Article  PubMed  Google Scholar 

  30. Giannini E, Risso D, Botta F, Romagnoli P, Malfatti F, Fumagalli A, et al. Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems. J Intern Med. 2004;255(3):399–408.

    Article  CAS  PubMed  Google Scholar 

  31. Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004;40(6):1396–405. doi:10.1002/hep.20486.

    Article  PubMed  Google Scholar 

  32. Kondo K, Chijiiwa K, Nagano M, Hiyoshi M, Kai M, Maehara N, et al. Comparison of seven prognostic staging systems in patients who undergo hepatectomy for hepatocellular carcinoma. Hepatogastroenterology. 2007;54(77):1534–8.

    PubMed  Google Scholar 

  33. Kitai S, Kudo M, Minami Y, Haji S, Osaki Y, Oka H, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncology. 2008;75(Suppl 1):83–90. doi:10.1159/000173428.

    Article  PubMed  Google Scholar 

  34. Kitai S, Kudo M, Izumi N, Kaneko S, Ku Y, Kokudo N, et al. Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score and BCLC system) in 4,649 cases from a Japanese nationwide survey. Dig Dis. 2014;32(6):717–24. doi:10.1159/000368008.

    Article  PubMed  Google Scholar 

  35. Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Chiou YY, et al. Differential prognostic impact of renal insufficiency on patients with hepatocellular carcinoma: a propensity score analysis and staging strategy. J Gastroenterol Hepatol. 2012;27(4):690–9. doi:10.1111/j.1440-1746.2011.06886.x.

    Article  PubMed  Google Scholar 

  36. Chen CF, Liu PH, Lee YH, Tsai YJ, Hsu CY, Huang YH, et al. Impact of renal insufficiency on patients with hepatocellular carcinoma undergoing radiofrequency ablation. J Gastroenterol Hepatol. 2015;30(1):192–8. doi:10.1111/jgh.12669.

    Article  PubMed  Google Scholar 

  37. Collette S, Bonnetain F, Paoletti X, Doffoel M, Bouche O, Raoul JL, et al. Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann Oncol. 2008;19(6):1117–26. doi:10.1093/annonc/mdn030.

    Article  CAS  PubMed  Google Scholar 

  38. Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Lee PC, et al. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer. 2010;116(12):3006–14. doi:10.1002/cncr.25044.

    Article  PubMed  Google Scholar 

  39. op den Winkel M, Nagel D, Sappl J, op den Winkel P, Lamerz R, Zech CJ et al. Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One. 2012;7(10):e45066. doi:10.1371/journal.pone.0045066.

    Google Scholar 

  40. Shao YY, Lu LC, Lin ZZ, Hsu C, Shen YC, Hsu CH, et al. Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems. Br J Cancer. 2012;107(10):1672–7. doi:10.1038/bjc.2012.466.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Lin ZZ, Hsu C, Hu FC, Shao YY, Chang DY, Yang CH, et al. Factors impacting prognosis prediction in BCLC stage C and Child-Pugh class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy. Oncologist. 2012;17(7):970–7. doi:10.1634/theoncologist.2011-0411.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Zhao JJ, Yan T, Zhao H, Zhou JG, Huang Z, Zhang YF, et al. Evaluation of eight different clinical staging systems associated with overall survival of chinese patients with hepatocellular carcinoma. Chin Med J (Engl). 2015;128(3):316–21. doi:10.4103/0366-6999.150095.

    Article  Google Scholar 

  43. Chan SL, Mo FK, Johnson PJ, Liem GS, Chan TC, Poon MC, et al. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J Gastroenterol Hepatol. 2011;26(2):340–7. doi:10.1111/j.1440-1746.2010.06329.x.

    Article  PubMed  Google Scholar 

  44. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, et al. Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol. 2005;100(8):1764–71. doi:10.1111/j.1572-0241.2005.41943.x.

    Article  PubMed  Google Scholar 

  45. Nanashima A, Sumida Y, Abo T, Shindou H, Fukuoka H, Takeshita H, et al. Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy. J Gastroenterol. 2006;41(3):250–6. doi:10.1007/s00535-005-1751-4.

    Article  PubMed  Google Scholar 

  46. Chan SL, Johnson PJ, Mo F, Berhane S, Teng M, Chan AW, et al. International validation of the Chinese university prognostic index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. Chin J Cancer. 2014;33(10):481–91. doi:10.5732/cjc.014.10133.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56(4):918–28.

    Article  CAS  PubMed  Google Scholar 

  48. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol. 1999;31(1):133–41.

    Google Scholar 

  49. The Cancer of the Liver Italian Program. (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology. 1998;28(3):751–5. doi:10.1002/hep.510280322.

    Article  Google Scholar 

  50. The Cancer of the Liver Italian Program. (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000;31(4):840–5. doi:10.1053/he.2000.5628.

    Article  Google Scholar 

  51. Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut. 2002;50(6):881–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Lin CY, Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, et al. Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. Liver Int. 2009;29(1):74–81. doi:10.1111/j.1478-3231.2008.01702.x.

    Article  PubMed  Google Scholar 

  53. Cho YK, Chung JW, Kim JK, Ahn YS, Kim MY, Park YO, et al. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer. 2008;112(2):352–61. doi:10.1002/cncr.23185.

    Article  CAS  PubMed  Google Scholar 

  54. Memon K, Kulik LM, Lewandowski RJ, Wang E, Wang J, Ryu RK, et al. Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization. J Vasc Interv Radiol. 2014;25(7):1056–66. doi:10.1016/j.jvir.2014.01.010.

    Article  PubMed  Google Scholar 

  55. Kaseb AO, Hassan MM, Lin E, Xiao L, Kumar V, Pathak P, et al. V-CLIP: integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer. 2011;117(11):2478–88. doi:10.1002/cncr.25791.

    Article  CAS  PubMed  Google Scholar 

  56. Kaseb AO, Abbruzzese JL, Vauthey JN, Aloia TA, Abdalla EK, Hassan MM, et al. I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology. 2011;80(5–6):373–81. doi:10.1159/000329040.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003;38(3):207–15. doi:10.1007/s005350300038.

    Article  PubMed  Google Scholar 

  58. Yamashita F, Tanaka M, Satomura S, Tanikawa K. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology. 1996;111(4):996–1001.

    Article  CAS  PubMed  Google Scholar 

  59. Nakao A, Taniguchi K, Inoue S, Takeda S, Harada A, Nonami T, et al. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies. Am J Gastroenterol. 1997;92(6):1031–4.

    CAS  PubMed  Google Scholar 

  60. Nanashima A, Sumida Y, Morino S, Yamaguchi H, Tanaka K, Shibasaki S, et al. The Japanese integrated staging score using liver damage grade for hepatocellular carcinoma in patients after hepatectomy. Eur J Surg Oncol. 2004;30(7):765–70. doi:10.1016/j.ejso.2004.05.003.

    Article  CAS  PubMed  Google Scholar 

  61. Ikai I, Takayasu K, Omata M, Okita K, Nakanuma Y, Matsuyama Y, et al. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterol. 2006;41(9):884–92. doi:10.1007/s00535-006-1878-y.

    Article  PubMed  Google Scholar 

  62. Lau H, Man K, Fan ST, Yu WC, Lo CM, Wong J. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg. 1997;84(9):1255–9.

    Article  CAS  PubMed  Google Scholar 

  63. Wakabayashi H, Ishimura K, Izuishi K, Karasawa Y, Maeta H. Evaluation of liver function for hepatic resection for hepatocellular carcinoma in the liver with damaged parenchyma. J Surg Res. 2004;116(2):248–52. doi:10.1016/j.jss.2003.09.015.

    Article  PubMed  Google Scholar 

  64. Omagari K, Honda S, Kadokawa Y, Isomoto H, Takeshima F, Hayashida K, et al. Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma. J Gastroenterol Hepatol. 2004;19(7):805–11. doi:10.1111/j.1440-1746.2004.03350.x.

    Article  PubMed  Google Scholar 

  65. Nanashima A, Omagari K, Sumida Y, Abo T, Fukuoha H, Takeshita H, et al. Evaluation of new prognostic staging systems (SLiDe score) for hepatocellular carcinoma patients who underwent hepatectomy. Hepatogastroenterology. 2009;56(93):1137–40.

    PubMed  Google Scholar 

  66. Kitai S, Kudo M, Minami Y, Ueshima K, Chung H, Hagiwara S, et al. A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score. Intervirology. 2008;51(Suppl 1):86–94. doi:10.1159/000122599.

    Article  CAS  PubMed  Google Scholar 

  67. Tateishi R, Yoshida H, Shiina S, Imamura H, Hasegawa K, Teratani T, et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut. 2005;54(3):419–25. doi:10.1136/gut.2003.035055.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, Loong CC, et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei integrated scoring system. J Hepatol. 2010;53(1):108–17. doi:10.1016/j.jhep.2010.01.038.

    Article  PubMed  Google Scholar 

  69. Toso C, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J, et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2008;14(8):1107–15. doi:10.1002/lt.21484.

    Article  PubMed  Google Scholar 

  70. Grat M, Kornasiewicz O, Holowko W, Lewandowski Z, Zieniewicz K, Paczek L, et al. Evaluation of total tumor volume and pretransplantation alpha-fetoprotein level as selection criteria for liver transplantation in patients with hepatocellular cancer. Transplant Proc. 2013;45(5):1899–903. doi:10.1016/j.transproceed.2012.12.010.

    Article  CAS  PubMed  Google Scholar 

  71. Li C, Wen TF, Yan LN, Li B, Yang JY, Xu MQ, et al. Scoring selection criteria including total tumour volume and pretransplant percentage of lymphocytes to predict recurrence of hepatocellular carcinoma after liver transplantation. PLoS One. 2013;8(8):e72235. doi:10.1371/journal.pone.0072235.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, et al. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Hepatology. 2015;62(1):158–65. doi:10.1002/hep.27787.

    Article  CAS  PubMed  Google Scholar 

  73. Kashkoush S, El Moghazy W, Kawahara T, Gala-Lopez B, Toso C, Kneteman NM. Three-dimensional tumor volume and serum alpha-fetoprotein are predictors of hepatocellular carcinoma recurrence after liver transplantation: refined selection criteria. Clin Transplant. 2014;28(6):728–36. doi:10.1111/ctr.12373.

    Article  CAS  PubMed  Google Scholar 

  74. Toyoda H, Kumada T, Osaki Y, Oka H, Urano F, Kudo M, et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol. 2006;4(12):1528–36. doi:10.1016/j.cgh.2006.09.021.

    Article  CAS  PubMed  Google Scholar 

  75. Fox R, Berhane S, Teng M, Cox T, Tada T, Toyoda H, et al. Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model. Br J Cancer. 2014;110(8):2090–8. doi:10.1038/bjc.2014.130.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Chan SL, Mo F, Johnson P, Li L, Tang N, Loong H, et al. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma. J Gastroenterol Hepatol. 2015;30(10):1529–35. doi:10.1111/jgh.13005.

    Article  CAS  PubMed  Google Scholar 

  77. Tokumitsu Y, Tamesa T, Matsukuma S, Hashimoto N, Maeda Y, Tokuhisa Y, et al. An accurate prognostic staging system for hepatocellular carcinoma patients after curative hepatectomy. Int J Oncol. 2015;46(3):944–52. doi:10.3892/ijo.2014.2798.

    PubMed  Google Scholar 

  78. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002;94(6):1760–9.

    Article  PubMed  Google Scholar 

  79. Yau T, Yao TJ, Chan P, Ng K, Fan ST, Poon RT. A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials. Cancer. 2008;113(10):2742–51. doi:10.1002/cncr.23878.

    Article  PubMed  Google Scholar 

  80. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–38. doi:10.1055/s-2007-1007122.

    Article  CAS  PubMed  Google Scholar 

  81. Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer. 2012;48(10):1452–65. doi:10.1016/j.ejca.2011.12.006.

    Article  CAS  PubMed  Google Scholar 

  82. Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, Lin CY, et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma—survival analysis of 3892 patients. Eur J Cancer. 2008;44(7):1000–6. doi:10.1016/j.ejca.2008.02.018.

    Article  PubMed  Google Scholar 

  83. Dufour JF, Bargellini I, De Maria N, De Simone P, Goulis I, Marinho RT. Intermediate hepatocellular carcinoma: current treatments and future perspectives. Ann Oncol. 2013;24 Suppl 2:ii24–9. doi:10.1093/annonc/mdt054.

    Google Scholar 

  84. Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, et al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32(4):348–59. doi:10.1055/s-0032-1329906.

    CAS  PubMed  Google Scholar 

  85. Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146(7):1691–700 e3. doi:10.1053/j.gastro.2014.02.032.

    Google Scholar 

  86. Kudo M. Real practice of hepatocellular carcinoma in Japan: conclusions of the Japan Society of Hepatology 2009 Kobe Congress. Oncology. 2010;78(Suppl 1):180–8. doi:10.1159/000315740.

    Article  PubMed  Google Scholar 

  87. Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford). 2005;7(1):35–41. doi:10.1080/13651820410024058.

    Article  Google Scholar 

  88. European Association for the Study of the Liver. European organisation for research and treatment of cancer. J Hepatol. 2012;56:908–43.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi, 755-8505, Japan

    Yukio Tokumitsu & Hiroaki Nagano

Authors
  1. Yukio Tokumitsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroaki Nagano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yukio Tokumitsu .

Editor information

Editors and Affiliations

  1. Dokuz Eylul University, Izmir Biomedicine and Genome Center Dokuz Eylul University, Izmir, Izmir, Turkey

    Brian I. Carr

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Tokumitsu, Y., Nagano, H. (2016). Current HCC Staging Systems: Their Uses and Limitations. In: Carr, B. (eds) Hepatocellular Carcinoma. Current Clinical Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-34214-6_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-34214-6_28

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-34212-2

  • Online ISBN: 978-3-319-34214-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation